ConsumerLab reviews the evidence for OsteoMD by 1MD, a bone health supplement promoted to slow bone loss and reduce the risk of osteoporosis
The study comprised a single intravenous (i.v.) administration of the peptide (20 g/kg in Sprague-Dawley rats and 6 g/kg in beagle dogs), a single intramuscular (i.m.) administration of 20, 100, or 500 g/kg (rats) and 6, 30, or 150 g/kg (dogs), and repeated i.m
Amount Range: 1.0 to 2.0 mg per administration within the research protocol examples
No finished-drug approval, no active IND, and no FDA-registered human clinical trials as of April 2026
- Reliable cold-chain shipping from certified distributors
Our Anti-Aging Therapy pairs the powerful regenerative effects of a NAD+ injection with a nutrient-rich IV drip packed with biotin and essential vitamins